Edition:
India

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

2.73USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
42,902
52-wk High
$7.68
52-wk Low
$2.54

Select another date:

BRIEF-Intracoastal Capital LLC Reports 9.2 Pct Passive Stake In RXI Pharmaceuticals Corp, As Of April 9

* INTRACOASTAL CAPITAL LLC REPORTS 9.2 PERCENT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP, AS OF APRIL 9, 2018 - SEC FILING Source text: [https://bit.ly/2vwj7uq] Further company coverage:

BRIEF-Lincoln Park Capital Reports 9.99 Pct Passive Stake In Rxi Pharmaceuticals

* LINCOLN PARK CAPITAL FUND, LLC REPORTS 9.99 PCT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP AS OF APRIL 9, 2018 SEC FILING Source: (https://bit.ly/2HzQ63m) Further company coverage:

BRIEF-Rxi Pharmaceuticals Announces Closing Of $4.9 Million Registered Direct Offering

* RXI PHARMACEUTICALS ANNOUNCES CLOSING OF $4.9 MILLION REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market

* RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Rxi Pharmaceuticals Files For Mixed Shelf Of Upto $100 Million

* RXI PHARMACEUTICALS CORP FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING Source text: (https://bit.ly/2If6FB2) Further company coverage:

BRIEF-RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​

* RXI - ON MARCH 20, DETERMINED INTERIM FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, JUNE 30, AND SEPT 30, 2017 SHOULD NO LONGER BE RELIED UPON‍​

BRIEF-RXi Pharmaceuticals Qtrly Loss Per Share $0.84

* RXI PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH

BRIEF-RXi Pharmaceuticals Announces Reverse Stock Split

* RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10

BRIEF-RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING

Select another date: